Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Coherus BioSciences targets profitability in 2024 with strong product focus

Coherus BioSciences is strategically positioned to achieve profitability in 2024 through revenue growth and cost control. The company's strong product portfolio and focus on user-friendly solutions provide a competitive edge. Challenges include competition and regulatory approvals, while opportunities exist in expanding product approvals and optimizing expenses.

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surface Oncology Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS). Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Co.

SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Marek Ciszewski – Senior Vice President-Investor Relations Denny Lanfear – President, CEO and Chairman Paul Reider – Chief Commercial Officer Theresa LaVallee – Chief Development Officer Rosh Dias – Chief Medical Officer McDavid Stilwell – Chief Financial Officer Conference Call Participants Robyn Karnauskas – Truist Securities Michael Nedelcovych – TD Cowen Douglas Tsao – H.C. Wainwright Chris Schott – JPMorgan Ash Verma – UBS Operator Good day and thank you for standing by.

Coherus BioSciences, Inc. (CHRS) Q2 2023 Earnings Call Transcript

– Net revenue rose 81% from prior quarter to $58.7 million – – CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter – – UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July – – Planned merger with Surface Oncology expected to significantly advance next-generation immuno-oncology pipeline – – Conference call today at 5:00 p.m. Eastern Daylight Time –

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

Pagaya Technologies Ltd

TC Biopharm Holdings PLC

Why would anyone want to buy penny stocks? They're extremely risky.

3 Hot Penny Stocks To Watch After TUP Stock Explodes, Again

REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023

– Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches –

Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today announced a national distribution agreement for YUSIMRY™ (adalimumab-aqvh) at a price of $995 per carton of two autoinjectors, a discount of more than 85% compared to Humira® (adalimumab), currently priced at $6,922 per carton of two pens. “Coherus is pleased to work with Superior Biologics for nationwide distribution of YUSIMRY, providing patients and their plan sponsors access to a high-quality, safe, and effective treatment at significant savings compared to Humira,” said Denny Lanfear, Coherus' Chairman and Chief Executive Officer. “Superior Biologics is an ideal partner for the distribution of YUSIMRY based on their commitment to quality patient service and care, their extensive experience working with manufacturers, patients, physicians, and plan sponsors, and their nationwide reach. Through this unique distribution partnership, we can bring YUSIMRY immediately to patients throughout the United States.”

Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™

KludeIn I Acquisition Corp

22nd Century Group

Ever heard of penny stocks? If you're new to investing, you might be scratching your head.

Best Penny Stocks To Buy Now? 3 To Watch Right Now

Here, I discuss my reasons for exiting the stock. My reasons are more or less specific to my situation. Thus, we can agree to disagree without being too disagreeable about it.

Coherus: Why I Am Exiting, But Also Why You May Want To Hold On

AbbVie

Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of over 85% to the blockbuster arthritis drug.

Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira

–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® –

Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.

SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF

Surface Oncology shares jumped by more than 16% on Friday morning after it was revealed the clinical-stage immuno-oncology (I-O) company is being acquired by Coherus BioSciences (NASDAQ:CHRS). The stock-for-stock transaction is valued at up to $65 million, approximately a three-fold premium over Surface's anticipated net cash of $20 million to $25 million at closing, the two companies said in a statement.

Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences

Coherus BioSciences Inc said on Thursday it had agreed to resolve a dispute over its plans to launch a lower-priced version of AbbVie Inc's Humira, its blockbuster rheumatoid arthritis drug.

Abbvie, Coherus agree to resolve dispute over Humira biosimilar

Big Lots

Caleres

Chico's FAS

CIRCOR

Designer Brands

G-III Apparel Group

Nabors Industries

Quanex Building Products

PacWest Bancorp

PRA Group

Rayonier Advanced Materials

Huge S&P 500 stocks dominated all year. But suddenly this month, investors are looking at scooping up much smaller companies for a song.

Here Are The 12 Small Stocks Everyone Suddenly Wants To Buy

– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients –

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma

Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's blockbuster arthritis drug Humira in July at a list price of $995 per carton, representing a discount of about 85% from Humira.

Coherus BioSciences to launch Humira biosimilar at $995 per carton

–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  –

Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients

REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date of any adalimumab offering in the United States.

Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023

Coherus BioSciences Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) flagged three observations at its partner Shanghai Junshi Biosciences Ltd's manufacturing site in China for its experimental cancer drug.

FDA flags issues at Coherus partner's China manufacturing site for cancer drug

Intercept Pharma

Surmodics

ViewRay

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)

– UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home –

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 1,764,705 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Coherus Prices Public Offering of Common Stock

REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock to be sold in the offering will be offered by Coherus. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Coherus Announces Proposed Public Offering of Common Stock

Coherus BioSciences, Inc. has several approved biosimilars such as UDENYCA, CIMERLI and YUSIMRY. Full-year 2023 net product sales of biosimilars expected to exceed $275 million.

News for Coherus BioSciences Stock (CHRS)